Publication Date
12-12-2022
Journal
Cancer Cell
DOI
10.1016/j.ccell.2022.09.017
PMID
36270276
PMCID
PMC10576652
PubMedCentral® Posted Date
10-14-2023
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Neoplasms, Precision Medicine, Prospective Studies, Medical Oncology
Abstract
3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.